INVESTOR ALERT: Investigation of Fortress Biotech, Inc. (FBIO) Announced by Holzer & Holzer, LLC

ATLANTA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) complied with federal securities laws. On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, Inc., announced that the FDA issued a Complete Response Letter (“CRL”) relating to the New Drug Application (“NDA”) for CUTX-101 and that the “CRL noted cGMP deficiencies had been observed at the facility where CUTX-101 is manufactured.”  Follow ...